Washington University or college School of Medicine in St. Louis (WashU Medicine) and BJC HealthCare are usually joining forces and partnering with CuriMeta, a brand new organization that will speed up lifesaving study in the fight against chronic and acute diseases that impact our communities. WashU Medicine plus BJC HealthCare are engaging in this venture to bring sophisticated data sets in support of analysis that seeks to predict, prevent and cure a broad variety of diseases, using advanced, state-of-the-art technologies to protect patient privacy and confidentiality.
CuriMeta’s unique capabilities include specialized expertise in managing “real-world” information collections, which hold great promise in terms of making research faster and more efficient. CuriMeta will create a secure platform to share such real-world data sets with life science companies whose study goals align with those of WashU Medicine plus BJC HealthCare, all while ensuring that will patients’ identities are kept private at every step in the process.
As part of their collaboration, WashU Medicine, BJC HealthCare and CuriMeta will certainly jointly select appropriate projects and collaborators. The collaborations will draw upon WashU Medicine’s experience in developing advanced methods to protect patient personal privacy, including the particular use of artificial intelligence (AI) to create “synthetic data” units, to ensure data shared by CuriMeta may be both high quality and meet current guidelines for safe and private health-data sharing.
“This company represents the new endeavor that is part of our own distinguished role as a science-driven academic health system, leveraging our analysis capabilities to continually plus exhaustively pursue ways to improve the wellness of the communities, ” said David H. Perlmutter, MD, executive vice chancellor for medical affairs, the George and Carol Bauer Dean associated with WashU Medication, and the Spencer T. plus Ann W. Olin Distinguished Professor. “We will assist CuriMeta in identifying and vetting research opportunities with appropriate life science companies. Few health-care institutions have the breadth and depth of clinical research resources of WashU Medicine and BJC in order to bring about this kind of big information endeavor. ”
Recently, real-life data models played an essential part in informing our collective response to the COVID-19 pandemic. Early within the public health emergency, hospitals plus physicians struggled to plan for surges of COVID-19 patients and to find safe and effective treatments. However , as more data was collected and used to enable research, scientists could a lot more precisely characterize patient subpopulations and disease severity. This information helped health-care providers determine how best to deliver care in order to those individuals. These same methods can now lead to advances in our understanding associated with numerous other diseases, enabling the identification of cutting-edge therapeutic strategies, often inside a fraction of the time and for a cheaper cost of more traditional medical studies.
For example, the particular analysis associated with large amounts of de-identified data from patients along with neurodegenerative illnesses could help researchers more accurately predict a timeline with regard to symptom progression and aid the design of clinical trials that investigate earlier interventions for those people. Similarly, studying de-identified data from patients who have experienced heart attacks may help forecast who eventually will develop heart failure plus identify the best preventive measures.
“With comprehensive, de-identified or synthetic information, it becomes possible to rapidly identify new diagnostic and treatment strategies that may work well for the given illness, ” said Philip R. O. Payne, PhD , the Janet and Bernard Becker Professor, chief data scientist and director associated with the Institute for Informatics at WashU Medicine. “For example, such data can help find new uses regarding existing drugs, and all those therapies may be delivered to market quickly and more cost efficiently, complementing our existing strengths in drug discovery plus clinical research, and in turn, providing more options to maintain health and treat disease. ”
A major emphasis intended for CuriMeta will be engaging with existence science collaborators focused on identifying brand new insights into cancer, cardiovascular disease, neurodegenerative diseases and other neurological conditions, as well as rare diseases and childhood illnesses – all clinical advantages at WashU Medicine plus BJC Health care. Such collaborative research efforts will help to determine new opportunities to diagnose, deal with and prevent disease, and ultimately enhance patient outcomes and high quality of lifestyle.
“We have the tools to shape our future, ” stated Richard J. Liekweg, president and chief executive officer of BJC HealthCare. “It’s our responsibility to use this unparalleled data system to chart elusive territory where curing, preventing plus predicting deadly or persistent illness is possible. ”
Davis Walp, founder and CEO of CuriMeta, added, “Health information plays an increasingly important function in the discovery, development plus appropriate make use of lifesaving interventions. Manufacturers invest billions each year to advance the particular science associated with medicine, yet there are still gaps within our understanding of the best way to diagnose, avoid and treat disease. CuriMeta, in collaboration with WashU Medicine and BJC HealthCare, will tap into rich wellness data in order to unlock evidence and insights that can connect individuals with lifesaving therapies within the potential. ”
More information about CuriMeta is available here .